Janux Therapeutics (NASDAQ:JANX) Now Covered by Guggenheim

Guggenheim assumed coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a research note released on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $72.00 target price on the stock.

A number of other brokerages have also issued reports on JANX. Piper Sandler started coverage on shares of Janux Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $42.00 price target on the stock. Raymond James Financial started coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They set an “outperform” rating and a $65.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $85.55.

Janux Therapeutics Stock Up 0.2%

Shares of JANX stock opened at $23.98 on Wednesday. The stock has a market capitalization of $1.44 billion, a PE ratio of -13.32 and a beta of 2.84. Janux Therapeutics has a 52-week low of $21.97 and a 52-week high of $71.71. The stock’s 50-day moving average price is $24.53 and its 200 day moving average price is $26.76.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Analysts expect that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Janux Therapeutics

Several large investors have recently modified their holdings of the business. RA Capital Management L.P. grew its position in shares of Janux Therapeutics by 7.9% in the first quarter. RA Capital Management L.P. now owns 11,189,693 shares of the company’s stock valued at $302,122,000 after purchasing an additional 824,041 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of Janux Therapeutics by 19.4% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,654,574 shares of the company’s stock valued at $98,673,000 after purchasing an additional 592,824 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock valued at $190,617,000 after purchasing an additional 1,038,996 shares during the last quarter. Paradigm Biocapital Advisors LP grew its position in shares of Janux Therapeutics by 46.5% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company’s stock valued at $188,246,000 after purchasing an additional 1,115,412 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Janux Therapeutics by 6.7% in the first quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company’s stock valued at $61,524,000 after purchasing an additional 142,328 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.